# Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

> **NCT06075264** · PHASE2 · RECRUITING · sponsor: **Frantz Viral Therapeutics, LLC** · enrollment: 27 (estimated)

## Conditions studied

- Vulvar Diseases
- HPV Infection
- Vulvar HSIL
- Pre-Cancerous Dysplasia
- HPV Disease
- VIN, Usual Type
- VIN 2 of Usual Type
- VIN 3 of Usual Type
- Vin II
- Vin III
- VIN Grade 2
- VIN Grade 3
- High Grade Intraepithelial Neoplasia

## Interventions

- **DRUG:** Artesunate ointment
- **DRUG:** Placebo ointment

## Key facts

- **NCT ID:** NCT06075264
- **Lead sponsor:** Frantz Viral Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075264, "Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06075264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*